Lara Pochintesta

Piacenza, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.

Journal: Haematologica

Published: September 25, 2023

Case Report: B Lymphocyte Disorders Under COVID-19 Inflammatory Pressure.

Case Report: B Lymphocyte Disorders Under COVID-19 Inflammatory Pressure.

Journal: Frontiers in oncology

Published: July 13, 2020

Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.

Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study.

Journal: Leukemia & lymphoma

Published: May 06, 2015

Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.

Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.

Journal: Leukemia & lymphoma

Published: October 28, 2014

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance.

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance.

Journal: Blood

Published: September 28, 2013

Psychological care of caregivers, nurses and physicians: a study of a new approach.

Psychological care of caregivers, nurses and physicians: a study of a new approach.

Journal: Cancer medicine

Published: September 26, 2013

Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.

Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.

Journal: Leukemia & lymphoma

Published: August 13, 2013

Monoclonal gammopathy of undetermined significance: a new proposal of workup.

Monoclonal gammopathy of undetermined significance: a new proposal of workup.

Journal: European journal of haematology

Published: July 11, 2013

Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.

Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.

Journal: PloS one

Published: June 21, 2013

Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.

Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.

Journal: British journal of haematology

Published: May 31, 2013

Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.

Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.

Journal: Leukemia & lymphoma

Published: February 28, 2013

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

Journal: American journal of hematology

Published: August 29, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026